FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2773485818> ?p ?o ?g. }

• W2773485818 endingPage "e43" @default.
• W2773485818 startingPage "e34" @default.
• W2773485818 abstract "Thrombocytopenia is a life-threatening complication in patients with advanced myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). In this study (ASPIRE), we aimed to assess eltrombopag, an oral thrombopoietin receptor agonist, for thrombocytopenia (grade 4) treatment in adult patients with advanced MDS or AML.ASPIRE consisted of an open-label, double-blind phase for 8 weeks and a randomised, double-blind phase (parts 1 and 2, reported here) for 12 weeks, and an open-label extension (part 3). Eligible patients were men and women aged 18 years or older, with intermediate-2 or high-risk MDS or AML, with bone marrow blasts of 50% or less, and had either grade 4 thrombocytopenia due to bone marrow insufficiency (platelet counts <25 × 109 per L) or grade 4 thrombocytopenia before platelet transfusion, with 25 × 109 platelets per L or greater after transfusion. Additionally, eligible patients had at least one of the following within the screening period of 4 weeks: platelet transfusion, symptomatic bleeding, or platelet count of less than 10 × 109 per L. During part 1, patients received eltrombopag, and dose-escalation criteria for part 2 were determined. In part 2, we randomly allocated patients 2:1 using an interactive voice-response system to eltrombopag or placebo, stratified by baseline platelet count (<10 × 109 platelets per L vs ≥10 × 109 platelets per L) and disease (MDS vs AML). In parts 1 and 2, patients received supportive standard of care and initiated eltrombopag or placebo at 100 mg per day (50 mg per day for patients of east-Asian heritage) to a maximum of 300 mg per day (150 mg per day for patients of east-Asian heritage). The part 2 primary objective was assessed by a composite primary endpoint of clinically relevant thrombocytopenic events (CRTE) during weeks 5-12, defined as one of the following events, either alone or in combination: grade 3 or worse haemorrhagic adverse events; platelet counts of less than 10 × 109 per L; or platelet transfusions. Efficacy analyses were based on intention to treat; clinically meaningful efficacy was defined as 30% absolute difference between groups. This trial is registered with ClinicalTrials.gov, number NCT01440374.In part 1, 17 patients received eltrombopag and 11 patients completed treatment; four experienced significantly increased platelet counts, and ten had reduced platelet transfusion requirements. In part 2 we randomly allocated 145 patients to receive supportive care plus eltrombopag (n=98) or placebo (n=47); similar proportions had MDS (50 [51%] patients to eltrombopag, 22 (47%) patients to placebo) or AML (48 [49%] patients to eltrombopag, 25 [53%] patients to placebo). Average weekly CRTE proportions from weeks 5-12 were significantly lower with eltrombopag (54% [95% CI 43-64]) than with placebo (69% [57-80], odds ratio [OR] 0·20, 95% CI 0·05-0·87; p=0·032) although the difference between treatment groups was less than 30%. The most common grade 3 and grade 4 adverse events were fatigue (six [6%] in the eltrombopag group and one [2%] in the placebo group), hypokalaemia (six [6%] and two [4%]), pneumonia (five [5%] and five [11%]), and febrile neutropenia (five [5%] and six [13%]). Serious adverse events were reported in 56 (58%) eltrombopag-treated patients and 32 (68%) placebo-treated patients. Seven eltrombopag recipients and two placebo recipients had serious adverse events that were suspected to be study drug-related (eltrombopag: acute kidney injury, arterial thrombosis, bone pain, diarrhoea, myocardial infarction, pyrexia, retinal vein occlusion, n=1 each; placebo: vomiting, white blood cell count increased, n=1 each). Two eltrombopag recipients (arterial thrombosis n=1; myocardial infarction n=1) and no placebo recipients experienced fatal serious adverse events suspected to be study drug-related.No new safety concerns were noted with eltrombopag and the trial met the primary objective of a reduction in CRTEs; eltrombopag might be a treatment option for thrombocytopenic patients with AML or MDS who are ineligible for other treatment and who are not receiving disease-modifying treatment.Novartis Pharma AG." @default.
• W2773485818 created "2017-12-22" @default.
• W2773485818 creator A5018345688 @default.
• W2773485818 creator A5020124946 @default.
• W2773485818 creator A5026388140 @default.
• W2773485818 creator A5030235127 @default.
• W2773485818 creator A5037134717 @default.
• W2773485818 creator A5041951303 @default.
• W2773485818 creator A5048794053 @default.
• W2773485818 creator A5057231642 @default.
• W2773485818 creator A5058925624 @default.
• W2773485818 creator A5062322697 @default.
• W2773485818 creator A5062968394 @default.
• W2773485818 creator A5079124367 @default.
• W2773485818 creator A5081490577 @default.
• W2773485818 creator A5084561034 @default.
• W2773485818 date "2018-01-01" @default.
• W2773485818 modified "2023-10-16" @default.
• W2773485818 title "Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial" @default.
• W2773485818 cites W1602160610 @default.
• W2773485818 cites W1998560266 @default.
• W2773485818 cites W2002311977 @default.
• W2773485818 cites W2049217001 @default.
• W2773485818 cites W2083671551 @default.
• W2773485818 cites W2103336749 @default.
• W2773485818 cites W2117418266 @default.
• W2773485818 cites W2125438418 @default.
• W2773485818 cites W2129510594 @default.
• W2773485818 cites W2150456410 @default.
• W2773485818 cites W2156831337 @default.
• W2773485818 cites W2170075800 @default.
• W2773485818 cites W2584597412 @default.
• W2773485818 cites W2979650617 @default.
• W2773485818 cites W2980079533 @default.
• W2773485818 cites W4245640489 @default.
• W2773485818 doi "https://doi.org/10.1016/s2352-3026(17)30228-4" @default.
• W2773485818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29241762" @default.
• W2773485818 hasPublicationYear "2018" @default.
• W2773485818 type Work @default.
• W2773485818 sameAs 2773485818 @default.
• W2773485818 citedByCount "72" @default.
• W2773485818 countsByYear W27734858182018 @default.
• W2773485818 countsByYear W27734858182019 @default.
• W2773485818 countsByYear W27734858182020 @default.
• W2773485818 countsByYear W27734858182021 @default.
• W2773485818 countsByYear W27734858182022 @default.
• W2773485818 countsByYear W27734858182023 @default.
• W2773485818 crossrefType "journal-article" @default.
• W2773485818 hasAuthorship W2773485818A5018345688 @default.
• W2773485818 hasAuthorship W2773485818A5020124946 @default.
• W2773485818 hasAuthorship W2773485818A5026388140 @default.
• W2773485818 hasAuthorship W2773485818A5030235127 @default.
• W2773485818 hasAuthorship W2773485818A5037134717 @default.
• W2773485818 hasAuthorship W2773485818A5041951303 @default.
• W2773485818 hasAuthorship W2773485818A5048794053 @default.
• W2773485818 hasAuthorship W2773485818A5057231642 @default.
• W2773485818 hasAuthorship W2773485818A5058925624 @default.
• W2773485818 hasAuthorship W2773485818A5062322697 @default.
• W2773485818 hasAuthorship W2773485818A5062968394 @default.
• W2773485818 hasAuthorship W2773485818A5079124367 @default.
• W2773485818 hasAuthorship W2773485818A5081490577 @default.
• W2773485818 hasAuthorship W2773485818A5084561034 @default.
• W2773485818 hasConcept C109159458 @default.
• W2773485818 hasConcept C126322002 @default.
• W2773485818 hasConcept C141071460 @default.
• W2773485818 hasConcept C142724271 @default.
• W2773485818 hasConcept C204787440 @default.
• W2773485818 hasConcept C27081682 @default.
• W2773485818 hasConcept C2776689292 @default.
• W2773485818 hasConcept C2777863708 @default.
• W2773485818 hasConcept C2778713057 @default.
• W2773485818 hasConcept C2780007613 @default.
• W2773485818 hasConcept C2780240888 @default.
• W2773485818 hasConcept C2780588981 @default.
• W2773485818 hasConcept C2780817109 @default.
• W2773485818 hasConcept C28328180 @default.
• W2773485818 hasConcept C2993327898 @default.
• W2773485818 hasConcept C54355233 @default.
• W2773485818 hasConcept C71924100 @default.
• W2773485818 hasConcept C86803240 @default.
• W2773485818 hasConcept C89560881 @default.
• W2773485818 hasConcept C90924648 @default.
• W2773485818 hasConceptScore W2773485818C109159458 @default.
• W2773485818 hasConceptScore W2773485818C126322002 @default.
• W2773485818 hasConceptScore W2773485818C141071460 @default.
• W2773485818 hasConceptScore W2773485818C142724271 @default.
• W2773485818 hasConceptScore W2773485818C204787440 @default.
• W2773485818 hasConceptScore W2773485818C27081682 @default.
• W2773485818 hasConceptScore W2773485818C2776689292 @default.
• W2773485818 hasConceptScore W2773485818C2777863708 @default.
• W2773485818 hasConceptScore W2773485818C2778713057 @default.
• W2773485818 hasConceptScore W2773485818C2780007613 @default.
• W2773485818 hasConceptScore W2773485818C2780240888 @default.
• W2773485818 hasConceptScore W2773485818C2780588981 @default.
• W2773485818 hasConceptScore W2773485818C2780817109 @default.
• W2773485818 hasConceptScore W2773485818C28328180 @default.
• W2773485818 hasConceptScore W2773485818C2993327898 @default.
• W2773485818 hasConceptScore W2773485818C54355233 @default.

• next